New York Society of Addiction Medicine
August 1, 2019 by NYSAMKey Issues
July 24, 2019 The Honorable Andrew M. Cuomo Governor of New York State NYS State Capitol Building Albany, NY 12224…
July 30, 2019 by NYSAMKey Issues
ASAM Board Member, Dr. Margaret Jarvis, testified in front of a Congressional Roundtable on the nation’s response to the “third…
July 23, 2019 by Edwin SalsitzKey Issues
Language Matters We have witnessed remarkable progress in the understanding of the disease of addiction over the past two decades.…
July 16, 2019 by NYSAMKey Issues
NYSAM board members Dr. Melissa Weimer and Dr. Jeffrey Selzer together with Dr. Daniel Schatz, adjunct assistant professor in the…
May 2, 2019 by NYSAMKey Issues
“Drunk with Hope”, written by Tara Handron, will debut in Syracuse, NY in May. NYSAM board member Dr. Dorothy Lennon…
April 12, 2019 by Daniel Schatz, MDKey Issues
The New York State Department of Health, the New York State Office of Alcoholism and Substance Abuse (OASAS), and the New York State Buprenorphine Working Group wrote a Best Practice document focused on misconceptions related to the use of buprenorphine for the treatment of opioid use disorder (OUD). NYSAM Board Member, Dr. Dan Schatz, wrote a summary of the document reviewing five misconceptions of buprenorphine treatment.